Markets:

Overview

News

Currencies

International

Treasuries

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

25.15 +1.27 (+5.32%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Syndax Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗

March 26, 2026

Via Chartmill

This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset ↗

March 21, 2026

This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.

Via The Motley Fool

Topics Regulatory Compliance

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

This biotechnology firm develops precision therapies for rare, genetically defined diseases, with a focus on targeted cancer treatments.

Via The Motley Fool

Topics Regulatory Compliance

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops antibody therapies for thyroid eye disease, advancing multiple candidates through its R&D pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q4 2025 Results with Revenue Beat and Wider-Than-Expected Loss ↗

February 26, 2026

Via Chartmill

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.

Via The Motley Fool

Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment ↗

March 13, 2026

This clinical-stage biotech develops oncology therapeutics and partners with leading institutions in cancer and immunology research.

Via The Motley Fool

Topics Regulatory Compliance

Syndax Pharmaceuticals's Earnings Outlook ↗

October 31, 2025

Via Benzinga

SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval ↗

October 24, 2025

Via Stocktwits

Earnings Scheduled For August 4, 2025 ↗

August 04, 2025

Via Benzinga

Biotech Stock Up 365% as This $8 Million Investment Targets a Drug With 3 NDA Filings Planned ↗

March 13, 2026

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.

Via The Motley Fool

Topics Regulatory Compliance

Syndax (SNDX) Q4 2025 Earnings Call Transcript ↗

February 27, 2026

Syndax (SNDX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally

December 22, 2025

As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...

Via MarketMinute

Topics ETFs Economy Intellectual Property

Syndax Pharmaceuticals's Earnings: A Preview ↗

August 01, 2025

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 03, 2025

Via Benzinga

Why Is Syndax Stock Down Today? ↗

October 24, 2025

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) are trading lower Friday following approval of one of its treatments from the U.S.'s Food and Drug Administration.

Via Benzinga

Where Syndax Pharmaceuticals Stands With Analysts ↗

October 16, 2025

Via Benzinga

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth ↗

September 04, 2025

Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.

Via Benzinga

This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

September 04, 2025

Via Benzinga

Earnings Scheduled For May 5, 2025 ↗

May 05, 2025

Via Benzinga

Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗

September 04, 2025

Via Benzinga

Syndax (SNDX) Q2 Revenue Jumps 986% ↗

August 04, 2025

Via The Motley Fool

Topics Intellectual Property

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower EPS Loss ↗

August 04, 2025

Syndax Pharmaceuticals reported mixed Q2 2025 results, beating revenue estimates with $37.96M but posting an EPS loss of ($0.83). Revuforj sales surged 43%, while shares dipped 3.66% post-earnings.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

May 20, 2025

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.

Via Chartmill

Agilysys, Amer Sports, X Financial And Other Big Stocks Moving Higher On Tuesday ↗

May 20, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

May 06, 2025

Via Benzinga

NXP Semiconductors, Brinker International, Ultra Clean, Sanmina And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

April 29, 2025

Via Benzinga

Why Leggett & Platt Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

April 29, 2025

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Syndax Pharmaceuticals, Inc. - Common Stock (NQ:SNDX)

Headline News about Syndax Pharmaceuticals, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today